Compass Therapeutics Inc (NASDAQ:CMPX) has a beta value of 0.76 and has seen 0.57 million shares traded in the last trading session. The company, currently valued at $227.02M, closed the last trade at $1.65 per share which meant it gained $0.22 on the day or 15.38% during that session. The CMPX stock price is -41.82% off its 52-week high price of $2.34 and 53.94% above the 52-week low of $0.76. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.37 million shares traded. The 3-month trading volume is 477.29K shares.
The consensus among analysts is that Compass Therapeutics Inc (CMPX) is Buy stock at the moment, with a recommendation rating of 1.38. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.09.
Compass Therapeutics Inc (NASDAQ:CMPX) trade information
Sporting 15.38% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CMPX stock price touched $1.65 or saw a rise of 2.37%. Year-to-date, Compass Therapeutics Inc shares have moved 13.79%, while the 5-day performance has seen it change 13.79%. Over the past 30 days, the shares of Compass Therapeutics Inc (NASDAQ:CMPX) have changed -0.60%. Short interest in the company has seen 2.1 million shares shorted with days to cover at 4.14.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 67.0% from current levels. The projected low price target is $5.0 while the price target rests at a high of $5.0. In that case, then, we find that the current price level is -203.03% off the targeted high while a plunge would see the stock gain -203.03% from current levels.
Compass Therapeutics Inc (CMPX) estimates and forecasts
Figures show that Compass Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 73.30% over the past 6 months, with this year growth rate of -6.06%, compared to 17.00% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 12.88% over the past 5 years.
CMPX Dividends
Compass Therapeutics Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Compass Therapeutics Inc (NASDAQ:CMPX)’s Major holders
Insiders own 12.55% of the company shares, while shares held by institutions stand at 69.16% with a share float percentage of 79.09%. Investors are also buoyed by the number of investors in a company, with Compass Therapeutics Inc having a total of 109.0 institutions that hold shares in the company. The top two institutional holders are ORBIMED ADVISORS LLC with over 22.36 million shares worth more than $22.36 million. As of 2024-06-30, ORBIMED ADVISORS LLC held 16.3701% of shares outstanding.
The other major institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., with the holding of over 11.13 million shares as of 2024-06-30. The firm’s total holdings are worth over $11.13 million and represent 8.1474% of shares outstanding.
